Despite the positive outlook, Stifel acknowledges risks that could slow Travis Perkins’ recovery. The Merchanting division’s turnaround is not yet evident in financial results, with like-for-like ...

Stifel analyst Annabel Samimy initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $45 price target Palvella, which ...

Kailera jumped the weight loss miracle-drug line by licensing four clinical-stage obesity therapies from China, which is ...

The president’s executive order promising to lower pharmaceutical prices includes support for a fix long sought by the ...

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.

Stifel analysts said that Lexeo’s data showing reduced size and thickness of the heart’s left ventricle are “supportive of a drug effect” for the company’s gene therapy in Friedreich’s ataxia ...

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual ... company is efficiently building next generation ...

With a "terrible" job market, empty labs, and mounting competition from China, the lifeblood of Kendall Square is under ...

We recently published a list of Top 10 Restaurant Stocks to Buy Under $20. In this article, we are going to take a look at ...

So I think that's how I would think about it. It's not a departure. It's a building around, it is a diversification. Yes. Excellent. So I think overall, just stepping back Dravet is a very serious ...

"The changing momentum on what the market is looking for on tariffs and the volatility in the equity market is spilling over ...